Habis M, Morice M C
Centre Hospitalier Emile Roux, Eaubonne.
Ann Cardiol Angeiol (Paris). 1998 Jan;47(1):22-31.
Antithrombotic treatment of unstable angina is a highly controversial subject. The development of new antithrombotics (anti Gp IIb-IIIa, hirudin) has led to numerous therapeutic trials. Anti Gp IIb-IIIa are very promising in this indication, especially the Reopro chimeric antibody (Abciximab). Hirudin and its derivatives have demonstrated an early, but ephemeral clinical benefit. Low molecular weight heparins appear to be more effective than non-fractioned heparin and are easier and safer to use.
不稳定型心绞痛的抗栓治疗是一个极具争议的话题。新型抗栓药物（抗糖蛋白IIb-IIIa、水蛭素）的研发引发了众多治疗试验。抗糖蛋白IIb-IIIa在这一适应症中前景广阔，尤其是Reopro嵌合抗体（阿昔单抗）。水蛭素及其衍生物已显示出早期但短暂的临床益处。低分子量肝素似乎比普通肝素更有效，且使用起来更简便、更安全。
